Adaptimmune Therapeutics PLC
ADAP
Company Profile
Business description
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Contact
60 Jubilee Avenue
Milton Park
AbingdonOxfordshireOX14 4RY
GBRT: +44 1235430000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
506
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,106.88 | 187.26 | 2.36% |
| DAX 40 | 24,252.80 | 15.86 | 0.07% |
| Dow JONES (US) | 46,270.46 | 202.88 | 0.44% |
| FTSE 100 | 9,450.96 | 1.81 | -0.02% |
| HKSE | 25,978.11 | 536.76 | 2.11% |
| NASDAQ | 22,521.70 | 172.91 | -0.76% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
| S&P 500 | 6,644.31 | 10.41 | -0.16% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |